Silver Book Fact

Vaccine-eligible account for majority of shingles-related hospitalizations

The shingles vaccine-eligible population (i.e., persons aged 60 years or older) accounted for 74% of the total annual shingles-related hospital charges in 2004.

Patel, Mitesh S., Achamyeleh Gebremariaum, and Matthew M. Davis. Herpes Zoster-Related Hospitalizations and Expenditures Before and After Introduction of the Varicella Vaccine in the United States. Infect Control Hosp Epidemiol. 2008; 29(12): 1157-63. http://www.ncbi.nlm.nih.gov/pubmed/18999945

Reference

Title
Herpes Zoster-Related Hospitalizations and Expenditures Before and After Introduction of the Varicella Vaccine in the United States
Publication
Infect Control Hosp Epidemiol
Publication Date
2008
Authors
Patel, Mitesh S., Achamyeleh Gebremariaum, and Matthew M. Davis
Volume & Issue
Volume 29, Issue 12
Pages
1157-63
URL
Read Full Resource

Categories

  • Cost of Disease
  • Human Burden

Related Facts

  • Drug-resistant MRSA expensive to treat
    As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.  
  • 1 in 2 people who live to 85 will get shingles
    Around 1 in 2 people who live to be 85 will get shingles.  
  • Around $35 billion cost to society from antibiotic resistant infections
    The societal costs of antibiotic resistant infections are around $35 billion each year- this includes the cost of lost wages and premature deaths.  
  • Annual cost of shingles
    Shingles cost ~$1 billion in indirect and direct medical expenses each year.  
  • Cost of vaccine-preventable diseases
    Vaccine-preventable diseases relevant to the ten vaccines recommended for US adults, cost an estimated $9 billion in 2015.